celecoxib has been researched along with Anorexia in 5 studies
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies reported promising efficacy for celecoxib in the treatment of cancer cachexia." | 9.27 | Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers. ( Ala, S; Alipour, A; Borhani, S; Janbabai, G; Kouchaki, B; Salehifar, E, 2018) |
| " antioxidants) with carnitine + celecoxib ± megestrol acetate for the treatment of cancer-related anorexia/cachexia syndrome (CACS): the primary endpoints were increase of lean body mass (LBM) and improvement of total daily physical activity." | 9.16 | Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. ( Antoni, G; Astara, G; Cau, MC; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Mela, Q; Montaldo, L; Mura, M; Panzone, F; Serpe, R; Tanca, FM, 2012) |
| "Previous studies reported promising efficacy for celecoxib in the treatment of cancer cachexia." | 5.27 | Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers. ( Ala, S; Alipour, A; Borhani, S; Janbabai, G; Kouchaki, B; Salehifar, E, 2018) |
| " antioxidants) with carnitine + celecoxib ± megestrol acetate for the treatment of cancer-related anorexia/cachexia syndrome (CACS): the primary endpoints were increase of lean body mass (LBM) and improvement of total daily physical activity." | 5.16 | Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. ( Antoni, G; Astara, G; Cau, MC; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Mela, Q; Montaldo, L; Mura, M; Panzone, F; Serpe, R; Tanca, FM, 2012) |
| "Celecoxib 400 mg was taken orally twice daily during chemoradiation, up to 1 week before surgery, and for 6 months following surgery." | 2.82 | Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. ( Bueno, R; Choi, N; Cleary, JM; Donahue, DM; Enzinger, PC; Fidias, PM; Fuchs, CS; Gaissert, HA; Jaklitsch, MT; Kulke, MH; Lynch, TP; Mamon, HJ; Mentzer, SJ; Meyerhardt, JA; Swanson, RS; Szymonifka, J; Wain, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kouchaki, B | 1 |
| Janbabai, G | 1 |
| Alipour, A | 1 |
| Ala, S | 1 |
| Borhani, S | 1 |
| Salehifar, E | 1 |
| Cleary, JM | 1 |
| Mamon, HJ | 1 |
| Szymonifka, J | 1 |
| Bueno, R | 1 |
| Choi, N | 1 |
| Donahue, DM | 1 |
| Fidias, PM | 1 |
| Gaissert, HA | 1 |
| Jaklitsch, MT | 1 |
| Kulke, MH | 1 |
| Lynch, TP | 1 |
| Mentzer, SJ | 1 |
| Meyerhardt, JA | 1 |
| Swanson, RS | 1 |
| Wain, J | 1 |
| Fuchs, CS | 1 |
| Enzinger, PC | 1 |
| Madeddu, C | 2 |
| Dessì, M | 1 |
| Panzone, F | 1 |
| Serpe, R | 2 |
| Antoni, G | 1 |
| Cau, MC | 1 |
| Montaldo, L | 1 |
| Mela, Q | 1 |
| Mura, M | 1 |
| Astara, G | 2 |
| Tanca, FM | 1 |
| Macciò, A | 2 |
| Mantovani, G | 2 |
| Yamamoto, K | 1 |
| Asano, K | 1 |
| Ito, Y | 1 |
| Matsukawa, N | 1 |
| Kim, S | 1 |
| Yamatodani, A | 1 |
| Gramignano, G | 1 |
| Lusso, MR | 1 |
| Massa, E | 1 |
| Deiana, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Cisplatin, CPT-11, Celecoxib (PCC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer[NCT00137852] | Phase 2 | 35 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy[NCT02644408] | Phase 3 | 184 participants (Actual) | Interventional | 2014-10-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for celecoxib and Anorexia
| Article | Year |
|---|---|
Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers.
Topics: Anorexia; Antineoplastic Agents, Hormonal; Cachexia; Celecoxib; Combined Modality Therapy; Double-Bl | 2018 |
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2016 |
Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Anorexia; Appetite; Cachexia; Carnitine; Celecoxib; | 2012 |
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress.
Topics: Adult; Aged; Anorexia; Ascorbic Acid; Cachexia; Carbocysteine; Celecoxib; Dietary Supplements; Docos | 2006 |
1 other study available for celecoxib and Anorexia
| Article | Year |
|---|---|
Involvement of hypothalamic cyclooxygenase-2, interleukin-1β and melanocortin in the development of docetaxel-induced anorexia in rats.
Topics: Animals; Anorexia; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Docetaxel; Hypothalamus | 2012 |